Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study
Chad A Bousman, Daniel J Mueller, Chee H Ng, Keith Byron, Michael Berk, Ajeet B Singh
Pharmacogenetics and Genomics | LIPPINCOTT WILLIAMS & WILKINS | Published : 2017
Awarded by NHMRC
This study was supported in part by a 2012 Pfizer Australia NSR grant (A.S.). C.B. was supported by a University of Melbourne, Ronald Phillip Griffith Fellowship. M.B. is supported by an NHMRC Senior Principal Research Fellowship (1059660).